Aptamer Details

Back to Search Results

CCRF-CEM (sgc8c) (ID# 7813)

Aptamer Chemistry: DNA

Target: Acute lymphoblastic leukemia (CCRF-CEM)

Antigen/Target Category: Cells

Affinity (Kd): 0.78 nM (reported value)

Binding Conditions/Buffer: Binding buffer: 0.1mg/ml yeast tRNA and 1 mg/ml BSA into wash buffer (4.5g/L glucose, 5 mM MgCl₂ in Dulbecco's PBS with CaCl₂ and MgCl₂)

Binding Temp: 4°C

Refolding Protocol: NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.

Specificity: Recognizes and binds to cell lines Molt-4 (T cell Acute Lymphoblastic Leukemia [ALL]), Sup-T1 (T cell ALL), and Jurkat (T cell ALL).

Comments: This aptamer is a truncated version of sgc8.
Huang et al. (2009) conjugated doxorubicin to sgc8c through a hydrazone linker. The sgc8c-doxorubicin conjugate was internalized through receptor-mediated uptake and doxorubicin was released in the endosome. This lead to an increase in toxicity to CCRF-CEM cells of 6.7-fold compared to NB-4 cells. The binding affinity (Kd) of the conjugate was comparable to the unconjugated sgc8c aptamer (2.0 nM).

Sequence ():

Length: 41

Molecular Weight: 12634.26

Extinction Coefficient: 397600

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Reference:

Sequence:
Shangguan et al. "Optimization and Modifications of Aptamers Selected from Live Cancer Cell Lines." Chem. Biochem., 8, (2007): 603-6.

Doxorubicin conjugation:
Y-F Huang et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem. 10(2009):862-868.

Have your aptamer oligo synthesized ORDER